INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. Bimatoprost ophthalmic solution 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.. Bimatoprost ophthalmic solution 0.03% is prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. (1).

LACTATION SECTION.

8.2 Lactation. Risk SummaryIt is not known whether topical ocular treatment with bimatoprost ophthalmic solution 0.03% could result in sufficient systemic absorption to produce detectable quantities in human milk. In animal studies, bimatoprost has been shown to be present in breast milk of lactating rats at an intravenous dose (i.e., mg/kg) 324 times the RHOD (on m 2g/m basis), however no animal data is available at clinically relevant doses. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for bimatoprost ophthalmic solution, 0.03% and any potential adverse effects on the breastfed child from bimatoprost ophthalmic solution, 0.03%.

MECHANISM OF ACTION SECTION.

12.1 Mechanism of Action. Bimatoprost, prostaglandin analog, is synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Carcinogenesis Bimatoprost was not carcinogenic in either mice or rats when administered by oral gavage for 104 weeks at doses of up to mg/kg/day and mg/kg/day respectively (at least 192 and 291 times the human systemic exposure at the RHOD, respectively, based on blood AUC levels).Mutagenesis Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the in vivo mouse micronucleus tests. Impairment of Fertility Bimatoprost did not impair fertility in male or female rats at doses up to 0.6 mg/kg/day (at least 103 times the human systemic exposure at the RHOD, based on blood AUC levels).

OVERDOSAGE SECTION.

10 OVERDOSAGE. No information is available on overdosage in humans. If overdose with bimatoprost ophthalmic solution, 0.03% occurs, treatment should be symptomatic.In oral (by gavage) mouse and rat general toxicity studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m is at least 70 times higher than the accidental dose of one bottle of bimatoprost ophthalmic solution, 0.03% for 10 kg child.

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following adverse reactions are described elsewhere in the labeling:Pigmentation [see Warnings and Precautions (5.1)] Eyelash Changes [see Warnings and Precautions (5.2)] Intraocular Inflammation [see Warnings and Precautions (5.3)] Macular Edema [see Warnings and Precautions (5.4)] Hypersensitivity [see Contraindications (4)] Pigmentation [see Warnings and Precautions (5.1)] Eyelash Changes [see Warnings and Precautions (5.2)] Intraocular Inflammation [see Warnings and Precautions (5.3)] Macular Edema [see Warnings and Precautions (5.4)] Hypersensitivity [see Contraindications (4)] Most common adverse reaction is conjunctival hyperemia (45%). (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs Limited at 1-855-839-8195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.In clinical trials, the most frequent events associated with the use of bimatoprost ophthalmic solution, 0.03% occurring in approximately 15% to 45% of patients, in descending order of incidence, included conjunctival hyperemia, growth of eyelashes, and ocular pruritus. Approximately 3% of patients discontinued therapy due to conjunctival hyperemia.Ocular adverse events occurring in approximately to 10% of patients, in descending order of incidence, included ocular dryness, visual disturbance, ocular burning, foreign body sensation, eye pain, pigmentation of the periocular skin, blepharitis, cataract, superficial punctate keratitis, periorbital erythema, ocular irritation, and eyelash darkening. The following ocular adverse events reported in approximately to 3% of patients, in descending order of incidence, included: eye discharge, tearing, photophobia, allergic conjunctivitis, asthenopia, increases in iris pigmentation, and conjunctival edema. In less than 1% of patients, intraocular inflammation was reported as iritis. Systemic adverse events reported in approximately 10% of patients were infections (primarily colds and upper respiratory tract infections). The following systemic adverse events reported in approximately 1to 5% of patients, in descending order of incidence, included headaches, abnormal liver function tests, asthenia and hirsutism.. 6.2 Postmarketing Experience. The following adverse reactions have been identified during postapproval use of bimatoprost ophthal mic solution 0.03%. Because these reactions are reported voluntarily from population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to bimatoprost ophthal mic solution 0.03%, or combination of these factors, include: abnormal hair growth, asthma-like symptoms, dizziness, dyspnea, eyelid edema, hypersensitivity reaction including signs and symptoms of eye allergy and allergic dermatitis, hypertension, nausea, and periorbital and lid changes including deepening of the eyelid sulcus, and skin discoloration (non-periocular).

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Carcinogenesis Bimatoprost was not carcinogenic in either mice or rats when administered by oral gavage for 104 weeks at doses of up to mg/kg/day and mg/kg/day respectively (at least 192 and 291 times the human systemic exposure at the RHOD, respectively, based on blood AUC levels).Mutagenesis Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the in vivo mouse micronucleus tests. Impairment of Fertility Bimatoprost did not impair fertility in male or female rats at doses up to 0.6 mg/kg/day (at least 103 times the human systemic exposure at the RHOD, based on blood AUC levels).

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Bimatoprost, prostaglandin analog, is synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.. 12.3 Pharmacokinetics. AbsorptionAfter one drop of bimatoprost ophthalmic solution 0.03% was administered once daily to both eyes of 15 healthy subjects for two weeks, blood concentrations peaked within 10 minutes after dosing and were below the lower limit of detection (0.025 ng/mL) in most subjects within 1.5 hours after dosing. Mean max and AUC to 24hr values were similar on days and 14 at approximately 0.08 ng/mL and 0.09 ngohr/mL, respectively, indicating that steady state was reached during the first week of ocular dosing. There was no significant systemic drug accumulation over time. DistributionBimatoprost is moderately distributed into body tissues with steady-state volume of distribution of 0.67 L/kg. In human blood, bimatoprost resides mainly in the plasma. Approximately 12% of bimatoprost remains unbound in human plasma. Elimination Metabolism Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form diverse variety of metabolites. Excretion Following an intravenous dose of radiolabeled bimatoprost (3.12 mcg/kg) to six healthy subjects, the maximum blood concentration of unchanged drug was 12.2 ng/mL and decreased rapidly with an elimination half-life of approximately 45 minutes. The total blood clearance of bimatoprost was 1.5 L/hr/kg. Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. In clinical studies of patients with open angle glaucoma or ocular hypertension with mean baseline IOP of 26 mmHg, the IOP-lowering effect of bimatoprost ophthalmic solution, 0.03% once daily (in the evening) was to mmHg.

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. Bimatoprost Bimatoprost ophthalmic solution 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see Adverse Reactions (6.2)]. Hypersensitivity. (4).

DESCRIPTION SECTION.

11 DESCRIPTION. Bimatoprost ophthalmic solution 0.03% is synthetic prostamide analog with ocular hypotensive activity. Its chemical name is Z)-7-[(1 R,2 R,3 R,5 S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-5- N-ethylheptenamide, and its molecular weight is 415.58. Its molecular formula is 25H 37NO 4. Its chemical structure is: Bimatoprost is powder, which is very soluble in ethyl alcohol and methyl alcohol and slightly soluble in water. Bimatoprost ophthalmic solution 0.03% is clear, colorless solution, practically free from particles with an osmolality of approximately 290 mOsmol/kg.Bimatoprost ophthalmic solution 0.03% contains Active: Bimatoprost 0.3 mg/mL; Preservative: benzalkonium chloride 0.05 mg/mL; Inactives: sodium chloride; Disodium hydrogen phosphate, heptahydrate, Citric acid monohydrate and water for injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.9 to 7.6.. structure.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. The recommended dosage is one drop in the affected eye(s) once daily in the evening. Bimatoprost ophthalmic solution 0.03% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.Reduction of the intraocular pressure starts approximately hours after the first administration with maximum effect reached within approximately to 12 hours.Bimatoprost ophthalmic solution 0.03% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.. One drop in the affected eye(s) once daily in the evening. (2).

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. Ophthalmic solution containing bimatoprost 0.3 mg/mL.. Ophthalmic solution containing 0.1 mg/mL bimatoprost. (3).

GERIATRIC USE SECTION.

8.5 Geriatric Use. No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. Bimatoprost ophthalmic solution 0.03% is supplied sterile in white low density polyethylene piece open nozzle container with cone shape, turquoise color TSTR- TEAR OFF caps available in following packs:2.5 mL fill in mL NDC 42571-128-355 mL fill in 10 mL NDC 42571-128-217.5 mL fill in 10 mL NDC 42571-128-28Storage: Store at to 25C (36 to 77F).

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL. NDC 42571-128-35 Bimatoprost Ophthalmic Solution 0.03% For Use in the Eyes Only 2.5 mL Label MICRO LABS LTD NDC 42571-128-35 Bimatoprost Ophthalmic Solution 0.03% For Use in the Eyes Only 2.5 mL Carton Label MICRO LABS LTD NDC 42571-128-21 Bimatoprost Ophthalmic Solution 0.03% For Use in the Eyes Only 5.0 mL Label MICRO LABS LTD NDC 42571-128-21 Bimatoprost Ophthalmic Solution 0.03% For Use in the Eyes Only 5.0 mL Carton Label MICRO LABS LTD NDC 42571-128-28 Bimatoprost Ophthalmic Solution 0.03% For Use in the Eyes Only 7.5 mL Label MICRO LABS LTD NDC 42571-128-28 Bimatoprost Ophthalmic Solution 0.03% For Use in the Eyes Only 7.5 mL Carton Label MICRO LABS LTD 2.5 mL label. 2.5 mL carton. mL label. mL carton. 7.5 mL label. 7.5 mL carton.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. AbsorptionAfter one drop of bimatoprost ophthalmic solution 0.03% was administered once daily to both eyes of 15 healthy subjects for two weeks, blood concentrations peaked within 10 minutes after dosing and were below the lower limit of detection (0.025 ng/mL) in most subjects within 1.5 hours after dosing. Mean max and AUC to 24hr values were similar on days and 14 at approximately 0.08 ng/mL and 0.09 ngohr/mL, respectively, indicating that steady state was reached during the first week of ocular dosing. There was no significant systemic drug accumulation over time. DistributionBimatoprost is moderately distributed into body tissues with steady-state volume of distribution of 0.67 L/kg. In human blood, bimatoprost resides mainly in the plasma. Approximately 12% of bimatoprost remains unbound in human plasma. Elimination Metabolism Bimatoprost is the major circulating species in the blood once it reaches the systemic circulation following ocular dosing. Bimatoprost then undergoes oxidation, N-deethylation and glucuronidation to form diverse variety of metabolites. Excretion Following an intravenous dose of radiolabeled bimatoprost (3.12 mcg/kg) to six healthy subjects, the maximum blood concentration of unchanged drug was 12.2 ng/mL and decreased rapidly with an elimination half-life of approximately 45 minutes. The total blood clearance of bimatoprost was 1.5 L/hr/kg. Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.

PREGNANCY SECTION.

8.1 Pregnancy. Risk SummaryThere are no adequate and well-controlled studies of bimatoprost ophthalmic solution 0.03% admin is tration in pregn ant women. There is no increase in the isk of major birth def ects or miscarri ages bas ed on bima toprost postmarketing experience.In embryofe tal develop mental studies, ad ministration of imatoprost in pregnant mice and ats during organogensis, resul ted in abortion and early del ivery at oral doses at least 33 imes (mice) or 94 times (rats) the human exposure at the recommended clinical dose (b as ed on blood area under the curve [AUC] leve ls). These adverse effe cts were not observed at 2.6 times (mice) and 47 times (rats) the human exposure at the recommended clinical dose.In pre/postna tal develop ment studies, adm inistration of imatoprost to pregnant rats from organogenesis to the end of la ctation resul ted in reduced es tation leng th and fetal body we ight, and incre as ed etal and pup mortality at oral doses at least 41 times the human syst emic exposure at the recommended clinical dose (based on blood AUC leve ls). No adverse effects were observed in rat offspring at exposures estimated at 14 times the human exposure at the recommended clinical dose (based on blood AUC levels).Because animal reprodu ctive studies are not always predict ive of human response bimatoprost ophthalmic solution 0.03% should be adm inistered during pregn ancy only if the po tential enefit justif ies the potent ial risk to the etus.DataAnimal DataIn an embryof etal deve lopment rat study, abortion was observed in pregnant rats administ ered bimatoprost orally dur ing organogenesis at 0.6 mg/kg/day (94 ti mes the human system ic exposure at the recommended human ophthalmic dose [RHOD], based on AUC). The No Observed Adverse Effe ct Level (NOAEL) for abort ion was 0.3 mg/kg/day es timated at 47 times the human systemic exposure at the RHOD, based on AUC). No abnormalities ere observed in rat etuses at doses up to 0.6 mg/kg /day.In an embryof etal deve lopment mouse study, abor tion and early elivery were observed in pregnant mi ce admin is tered bima toprost orally during organog enesis at doses greater than or equal to 0.3 mg/kg/day (33 ti mes the hu man sys temic exposure at the RHOD, based on AUC). The NOAEL for abortion and early del ivery was 0.1 mg/kg/day (2.6 times the human syst emic exposure at the RHOD, based on AUC). No abnormal ities were observed in mouse fetuses at doses up to 0.6 mg /kg/day (72 times the human systemic exposure at the RHOD, as ed on AUC).In pre/postn atal deve lopment study, tre atment of pregn ant rats with bim atoprost orally from es tation day to lac tation day 20 resul ted in reduced es tation leng th, increased la te resorptions, fetal deaths, and postnat al pup morta lity, and reduc ed pup body eight at doses grea ter than or equal to 0.3 mg/kg/day. Th ese effects were observed at exposur es at least 41 times the human syste mic exposure at the RHOD, based on AUC. The NOA EL for postnatal development and mating perfor mance of the offspring was 0.1 mg/kg/day es timated at 14 times the human systemic exposure at the RHOD, based on AUC).

SPL UNCLASSIFIED SECTION.

5.1 Pigmentation. Bimatoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of bimatoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known.Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with bimatoprost ophthalmic solution 0.03% can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use. (8.4) See 17 for PATIENT COUNSELING INFORMATION.Revised: 08/2019. 8.1 Pregnancy. Risk SummaryThere are no adequate and well-controlled studies of bimatoprost ophthalmic solution 0.03% admin is tration in pregn ant women. There is no increase in the isk of major birth def ects or miscarri ages bas ed on bima toprost postmarketing experience.In embryofe tal develop mental studies, ad ministration of imatoprost in pregnant mice and ats during organogensis, resul ted in abortion and early del ivery at oral doses at least 33 imes (mice) or 94 times (rats) the human exposure at the recommended clinical dose (b as ed on blood area under the curve [AUC] leve ls). These adverse effe cts were not observed at 2.6 times (mice) and 47 times (rats) the human exposure at the recommended clinical dose.In pre/postna tal develop ment studies, adm inistration of imatoprost to pregnant rats from organogenesis to the end of la ctation resul ted in reduced es tation leng th and fetal body we ight, and incre as ed etal and pup mortality at oral doses at least 41 times the human syst emic exposure at the recommended clinical dose (based on blood AUC leve ls). No adverse effects were observed in rat offspring at exposures estimated at 14 times the human exposure at the recommended clinical dose (based on blood AUC levels).Because animal reprodu ctive studies are not always predict ive of human response bimatoprost ophthalmic solution 0.03% should be adm inistered during pregn ancy only if the po tential enefit justif ies the potent ial risk to the etus.DataAnimal DataIn an embryof etal deve lopment rat study, abortion was observed in pregnant rats administ ered bimatoprost orally dur ing organogenesis at 0.6 mg/kg/day (94 ti mes the human system ic exposure at the recommended human ophthalmic dose [RHOD], based on AUC). The No Observed Adverse Effe ct Level (NOAEL) for abort ion was 0.3 mg/kg/day es timated at 47 times the human systemic exposure at the RHOD, based on AUC). No abnormalities ere observed in rat etuses at doses up to 0.6 mg/kg /day.In an embryof etal deve lopment mouse study, abor tion and early elivery were observed in pregnant mi ce admin is tered bima toprost orally during organog enesis at doses greater than or equal to 0.3 mg/kg/day (33 ti mes the hu man sys temic exposure at the RHOD, based on AUC). The NOAEL for abortion and early del ivery was 0.1 mg/kg/day (2.6 times the human syst emic exposure at the RHOD, based on AUC). No abnormal ities were observed in mouse fetuses at doses up to 0.6 mg /kg/day (72 times the human systemic exposure at the RHOD, as ed on AUC).In pre/postn atal deve lopment study, tre atment of pregn ant rats with bim atoprost orally from es tation day to lac tation day 20 resul ted in reduced es tation leng th, increased la te resorptions, fetal deaths, and postnat al pup morta lity, and reduc ed pup body eight at doses grea ter than or equal to 0.3 mg/kg/day. Th ese effects were observed at exposur es at least 41 times the human syste mic exposure at the RHOD, based on AUC. The NOA EL for postnatal development and mating perfor mance of the offspring was 0.1 mg/kg/day es timated at 14 times the human systemic exposure at the RHOD, based on AUC).. 8.2 Lactation. Risk SummaryIt is not known whether topical ocular treatment with bimatoprost ophthalmic solution 0.03% could result in sufficient systemic absorption to produce detectable quantities in human milk. In animal studies, bimatoprost has been shown to be present in breast milk of lactating rats at an intravenous dose (i.e., mg/kg) 324 times the RHOD (on m 2g/m basis), however no animal data is available at clinically relevant doses. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for bimatoprost ophthalmic solution, 0.03% and any potential adverse effects on the breastfed child from bimatoprost ophthalmic solution, 0.03%.. 8.4 Pediatric Use. Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.. 8.5 Geriatric Use. No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. (5.1) Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. (5.2) Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. (5.1) Eyelash Changes: Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. (5.2) 5.1 Pigmentation. Bimatoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of bimatoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long term effects of increased pigmentation are not known.Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with bimatoprost ophthalmic solution 0.03% can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.. 5.2 Eyelash Changes. Bimatoprost ophthalmic solution 0.03% may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and number of lashes. Eyelash changes are usually reversible upon discontinuation of treatment.. 5.3 Intraocular Inflammation. Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular inflammation. In addition, because these products may exacerbate inflammation, caution should be used in patients with active intraocular inflammation (e.g., uveitis).. 5.4 Macular Edema. Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution. Bimatoprost ophthalmic solution 0.03% should be used with caution in aphakic patients, in pseudophakic patients with torn posterior lens capsule, or in patients with known risk factors for macular edema.. 5.5 Bacterial Keratitis. There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had concurrent corneal disease or disruption of the ocular epithelial surface [see patient counseling information(17)]. 5.6 Contact Lens Use. Bimatoprost ophthalmic solution 0.03% contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses. Contact lenses should be removed prior to instillation of bimatoprost ophthal mic solution 0.03% and may be reinserted 15 minutes following its administration.

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Potential for Pigmentation Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent. Also inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of bimatoprost ophthalmic solution 0.03%. Potential for Eyelash ChangesInform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with bimatoprost ophthalmic solution 0.03%. These changes may result in disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment. Handling the ContainerInstruct patients to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. When to Seek Physician AdviceAdvise patients that if they develop an intercurrent ocular condition (e.g., trauma or infection), have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physicians advice concerning the continued use of bimatoprost ophthalmic solution 0.03%. Contact Lens UseAdvise patients that bimatoprost ophthalmic solution 0.03% contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of bimatoprost ophthalmic solution 0.03% and may be reinserted 15 minutes following its administration. Use with Other Ophthalmic DrugsAdvise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.Manufactured by: Micro Labs Limited Bangalore-560099. INDIA. Manufactured for: Micro Labs USA, Inc. Somerset, NJ 08873 Rev: 03/2022.

INSTRUCTIONS FOR USE SECTION.

INSTRUCTIONS FOR USE:. Bimatoprost Ophthalmic Solution 0.03% Before you use Bimatoprost Ophthalmic Solution 0.03% for the first time: 1.Check to make sure that the tamper evident ring between the bottle and the cap is not broken (See Figure A). If the tamper evident ring is broken or missing, contact your pharmacist. 2.Tear off the tamper evident ring (See Figure B).3.To open the bottle, remove the cap by turning it in the counterclockwise direction (See Figure C).This Instructions for Use has been approved by the U.S. Food and Drug Administration. Manufactured by: Micro Labs Limited Bangalore-560099. INDIA. Manufactured for: Micro Labs USA, Inc. Somerset, NJ 08873 Rev.03/2022 bimatoprost-inst-a.jpg. bimatoprost-inst-b.jpg. bimatoprost-inst-c.jpg.